Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Complicated Urinary Tract Infection Treatment Market?
Over the past few years, the intricate market for urinary tract infection treatment has seen robust growth. The market, which is projected to evolve from $8.87 billion in 2024 to $9.47 billion in 2025, is expected to experience a compound annual growth rate (CAGR) of 6.8%. The surge in growth during the historical period can be ascribed to factors such as a surge in urinary tract infection cases, an uptick in antibiotic resistance, an aging population, higher hospitalization rates, and heightened awareness about urinary tract infections.
What Growth Rate Is Forecasted for the Complicated Urinary Tract Infection Treatment Market by 2029?
Expectations are high for robust expansion in the complex urinary tract infection treatment market over the coming years. With a compound annual growth rate (CAGR) of 6.4%, predictions place the market value at $12.13 billion by 2029. This growth in the forecast period is primarily driven by factors such as increased incidences of multidrug-resistant bacteria, improved emphasis on precision medicine, growing healthcare expenditure, wider use of rapid diagnostic tests, as well as government-driven initiatives and funding for research. The period under the forecast also foresees major trends like the creation of novel antibiotics, diagnostic technique enhancements, broadening healthcare access in developing markets, advancements in diagnostic tool technology, and a surge in the adoption of combination therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21156&type=smp
Which Key Companies Are Shaping the Future of the Complicated Urinary Tract Infection Treatment Market?
Major companies operating in the complicated urinary tract infection treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Fresenius Kabi AG, GlaxoSmithKline plc, bioMérieux SA, Shionogi & Co. Ltd., Cipla Limited, Santen Pharmaceutical Co. Ltd., Orchid Pharma Limited, Melinta Therapeutics Inc., Spero Therapeutics Inc., Nabriva Therapeutics AG, Venatorx Pharmaceuticals Inc., Recce Pharmaceuticals Ltd, MerLion Pharmaceuticals Pte. Ltd., Entasis Therapeutics Holdings Inc., Allecra Therapeutics GmbH, Allergan Inc.
Which Factors Are Driving Demand in the Complicated Urinary Tract Infection Treatment Industry?
The complicated urinary tract infection treatment market is set to expand due to the increasing prevalence of chronic kidney diseases. Chronic kidney disease, or CKD, is a progressive condition marked by a slow deterioration of kidney function. The surge in CKD cases is mainly attributed to the escalating frequency of diabetes and hypertension, coupled with an aging population and lifestyle elements like obesity and smoking. Complicated urinary tract infection treatment aids CKD patients by combating severe infections like pyelonephritis, which can intensify kidney damage, impair renal function, and escalate the advancement of chronic kidney disease, thereby minimising the risk of further complications and hospital visits. For instance, data from the Australian Institute of Health and Welfare in December 2024 showed that CKD was accountable for about 21,800 deaths in Australia back in 2022. Moreover, Kidney Care UK, a non-profit organization based in the UK, indicated in May 2024 that there are 40-45,000 premature deaths caused by CKD in the UK each year. Consequently, the escalating prevalence of chronic kidney diseases propels the complicated urinary tract infection treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21156&type=smp
How Is the Complicated Urinary Tract Infection Treatment Market Segmented by Several Divisions?
The complicated urinary tract infection treatment market covered in this report is segmented –
1) By Drug Class: Penicillin And combinations, Quinolones, Cephalosporin, Azoles And Amphotericin B, Nitro furans
2) By Distribution Channel: Hospital Pharmacies, Gynecology And Urology Clinics, Drug stores
3) By Application: Urethritis, Cystitis, Pyelonephritis
Subsegments:
1) By Penicillin And Combinations: Aminopenicillins, Beta-Lactamase Inhibitor Combinations
2) By Quinolones: Fluoroquinolones, Non-Fluoroquinolones
3) By Cephalosporin: First-Generation Cephalosporins, Second-Generation Cephalosporins, Third-Generation Cephalosporins, Fourth-Generation Cephalosporins, Fifth-Generation Cephalosporins
4) By Azoles And Amphotericin B: Triazoles, Imidazoles, Polyene Antifungals
5) By Nitrofurans: Nitrofurantoin, Furazolidone
What are the Emerging Market Trends Driving the Growth of the Complicated Urinary Tract Infection Treatment Industry?
Leading enterprises in the complex urinary tract infection treatment market are concentrating on tackling antibiotic resistance by developing innovative antibiotics to boost treatment effectiveness and counteract emerging multidrug-resistant organisms. The approach towards treatment of complicated urinary tract infections involves using specific antibiotics or antimicrobial agents to eradicate or manage infections, especially in extreme scenarios where kidneys are affected. For example, Allecra Therapeutics, a biopharmaceutical firm based in Germany, received approval from the U.S. Food and Drug Administration (FDA) in February 2024 for using EXBLIFEP (cefepime/enmetazobactam) to treat complicated urinary tract infections (cUTIs) in adults. The firm also received a five-year extension on its marketing exclusivity thanks to the GAIN Act, encouraging the creation of fresh anti-infective treatments. The research revealed that 79.1% of patients given cefepime/enmetazobactam had a combined reaction (clinical cure and microbiological removal), as opposed to the 58.9% of patients treated with piperacillin/tazobactam.
Access The Full Report Here:
Which Regions Are Driving Growth in the Complicated Urinary Tract Infection Treatment Market?
North America was the largest region in the complicated urinary tract infection treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the complicated urinary tract infection treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21156
This Report Delivers Insight On:
1. How big is the complicated urinary tract infection treatment market, and how is it changing globally?
2. Who are the major companies in the complicated urinary tract infection treatment market, and how are they performing?
3. What are the key opportunities and risks in the complicated urinary tract infection treatment market right now?
4. Which products or customer segments are growing the most in the complicated urinary tract infection treatment market?
5. What factors are helping or slowing down the growth of the complicated urinary tract infection treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model